These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Hallucinations and delusions associated with Parkinson's disease psychosis: safety of current treatments and future directions. Isaacson SH; Citrome L Expert Opin Drug Saf; 2022 Jul; 21(7):873-879. PubMed ID: 35466847 [TBL] [Abstract][Full Text] [Related]
14. Pimavanserin for the treatment of Parkinson's disease psychosis. Friedman JH Expert Opin Pharmacother; 2013 Oct; 14(14):1969-75. PubMed ID: 24016069 [TBL] [Abstract][Full Text] [Related]
17. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905 [TBL] [Abstract][Full Text] [Related]
18. [Pimavanserin: a new treatment for the Parkinson's disease psychosis]. Duits JH; Ongering MS; Martens HJM; Schulte PFJ Tijdschr Psychiatr; 2017; 59(9):528-536. PubMed ID: 28880354 [TBL] [Abstract][Full Text] [Related]
19. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis. Hacksell U; Burstein ES; McFarland K; Mills RG; Williams H Neurochem Res; 2014 Oct; 39(10):2008-17. PubMed ID: 24682754 [TBL] [Abstract][Full Text] [Related]
20. Psychosis in Parkinson's Disease: Current Treatment Options and Impact on Patients and Caregivers. Segal GS; Xie SJ; Paracha SU; Grossberg GT J Geriatr Psychiatry Neurol; 2021 Jul; 34(4):274-279. PubMed ID: 34219522 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]